bestPWS, NCT02179151: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome |
|
|
| Terminated | 3 | 108 | US | ZGN-440 for Injectable Suspension, ZGN-440, Beloranib, ZGN-440 Placebo for Injectable Suspension, Placebo | Zafgen, Inc. | Prader-Willi Syndrome, Obesity | 12/15 | 10/16 | | |
